Ketanserin

Using ‘trip killers’ to cut short bad drug trips is potentially dangerous

Retrieved on: 
Wednesday, February 14, 2024

As interest in psychedelics has grown, so has interest in ways to end a bad trip.

Key Points: 
  • As interest in psychedelics has grown, so has interest in ways to end a bad trip.
  • Recent research reveals that people are giving potentially dangerous advice on social media on how to stop a trip that is less than pleasurable.
  • One of the earliest descriptions of a psychedelic experience in western literature can be found in Aldous Huxley’s 1953 book The Doors of Perception.
  • Research shows that if someone is in a bad mood or depressed then they are more likely to have a bad trip, as are people who take too high a dose.

Trip killers

  • Few clinical studies have examined trip killers, but one has found that ketanserin – a drug used to treat high blood pressure – reverses the psychedelic effects of LSD.
  • A recent article in the Emergency Medical Journal analysed posts on Reddit about trip killers.
  • Trip killers were discussed most often for LSD (235 posts), magic mushrooms (143 posts) and MDMA (21 posts).

Receptor blocking

  • To kill a trip then, one simply has to give the drug user another drug that blocks (rather than activates) the 5-HT2A receptor.
  • Many prescription drugs can do this and they tend to be antipsychotic drugs.
  • Quetiapine from the list above is one popular example, while another antipsychotic, olanzapine, was mentioned in 14 posts in that study.
  • Similarly, the atypical antidepressants trazodone and mirtazapine also block the 5-HT2A receptor.


Colin Davidson has previously received funding from the National Institute on Drug Abuse (NIH, USA) and the European Community for projects related to stimulant drug abuse and novel psychoactive compounds respectively. He is currently a paid consultant with the Defence Science Technology Laboratory (MOD) working on new psychoactive compounds.

MindMed Reports Full Year 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, March 9, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the full-year ended December 31, 2022.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the full-year ended December 31, 2022.
  • As of December 31, 2022, MindMed had cash and cash equivalents totaling $142.1 million compared to $133.5 million as of December 31, 2021.
  • MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s fiscal year 2022 financial results.
  • The webcast can be accessed live here on the Financials page in the Investors section of the MindMed website, https://mindmed.co/ .

MindMed's LSD Neutralizer Study Begins

Retrieved on: 
Wednesday, February 17, 2021

BASEL, Switzerland, Feb. 17, 2021 /PRNewswire/ --MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.

Key Points: 
  • BASEL, Switzerland, Feb. 17, 2021 /PRNewswire/ --MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.
  • As shown in studies in healthy volunteers, administration of the 5-HT2A receptor antagonist ketanserin prior to the administration of LSD almost completely prevents the acute effects of LSD.
  • The study hypothesis is that ketanserin (40 mg), administered to healthy humans one hour after taking LSD, significantly shortens and reduces the acute subjective effects of the LSD (100 g) compared to LSD alone (100 g) followed by a placebo.
  • This study will support the patent application that was filed last year (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.